Bank of America Securities Maintains "Buy" Rating for BioNTech (NASDAQ:BNTX)

• Bank of America Securities maintained its “Buy” rating for BioNTech (NASDAQ:BNTX) while lowering its price target to $128 from $134; shares are currently trading near $83.
• BioNTech co-founders Prof. Uğur Şahin and Prof. Özlem Türeci announced plans to establish an independent biotechnology company focused on next-generation mRNA innovations.
• Despite a 2025 net loss of €1.14 billion, BioNTech ended the year with a robust €17.2 billion in cash, cash equivalents and security investments.

On March 10, 2026, BioNTech (NASDAQ:BNTX) reported its fourth-quarter and full-year 2025 financial results alongside a major strategic announcement. Co-founders and current executives CEO Prof. Uğur Şahin and CMO Prof. Özlem Türeci plan to establish and lead an independent biotechnology company dedicated to advancing next-generation mRNA technologies. BioNTech will contribute certain intellectual property rights and mRNA platform technologies to the new venture in exchange for a minority equity stake, potential milestone payments and royalties. The co-founders are expected to complete their transition to the new company by the end of 2026 after their current service agreements expire. Binding agreements are anticipated by the end of the first half of 2026.

The move is designed to allow BioNTech to sharpen its strategic focus on its late-stage oncology pipeline. The company plans to have 15 Phase 3 clinical trials ongoing by the end of 2026, with multiple late-stage data readouts expected this year. BioNTech confirmed that its current development programs remain unchanged and on track.

Bank of America Securities maintained its “Buy” rating on the stock, citing the company’s strong cash position and progress toward becoming a multi-product oncology company.

The announcement, released together with the earnings results, triggered a sharp sell-off. BioNTech shares fell as much as 21% in early trading and were recently quoted around $83 (down approximately 18–19% from Friday’s close of $102.16). The stock fluctuated between a low of $79.52 and a high of $85.50, with trading volume exceeding 10.5 million shares. Market capitalization stood at approximately $20 billion.

For the full year 2025, BioNTech reported revenues of €2.87 billion and an IFRS net loss of €1.136 billion (approximately $1.33 billion), compared with a €665 million loss in 2024. The company ended the year with €17.2 billion in cash, cash equivalents and security investments. In the fourth quarter it posted an adjusted loss per share of approximately €0.33 (~38 cents in USD terms).

The Supervisory Board has begun a search for successors. BioNTech emphasized that the planned transition is intended to maximize long-term value for patients and shareholders, allowing the core company to focus on bringing new oncology therapies to market while the new venture advances cutting-edge mRNA platforms.